Sean Maduck has sold CORT and made no open-market buys since Dec 2018
Insider at Corcept Therapeutics Incorporated
SEC CIK 0001698310 · Filings on SEC.gov ↗
Every filing
30 filings since Dec 2018, newest first
CORCEPT THERAPEUTICS INC
Insider
CORCEPT THERAPEUTICS INC
Insider
CORCEPT THERAPEUTICS INC
Insider
CORCEPT THERAPEUTICS INC
Insider
CORCEPT THERAPEUTICS INC
Insider
CORCEPT THERAPEUTICS INC
Insider
CORCEPT THERAPEUTICS INC
Insider
CORCEPT THERAPEUTICS INC
Insider
CORCEPT THERAPEUTICS INC
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Chief Commercial Officer
Corcept Therapeutics Inc
Chief Commercial Officer
Corcept Therapeutics Inc
Chief Commercial Officer
Corcept Therapeutics Inc
Chief Commercial Officer
Corcept Therapeutics Inc
Insider
Corcept Therapeutics Inc
Insider
About Sean Maduck
Maduck Sean is a corporate insider and executive at Corcept Therapeutics Inc. (NASDAQ:CORT), where he is identified in SEC filings as an officer-level insider and is associated with the endocrinology business unit.( Public disclosures describe him as President, Corcept Endocrinology, a role in which he is involved in the company’s commercial operations around its endocrine-focused therapies, including products for conditions related to hypercortisolism.(
Maduck has been an active insider in Corcept Therapeutics’ equity, with multiple Form 4 and related filings reflecting both option grants and open-market or discretionary stock sales.( In one reported transaction, he received a grant of stock options covering 140,000 shares of Corcept Therapeutics stock, vesting in equal monthly installments over four years, contingent on his continued service with the company.( In separate transactions, he has reported significant sales of Corcept shares in his capacity as a senior executive, including multimillion‑dollar dispositions disclosed in regulatory filings and summarized in financial news coverage.( Detailed information about his prior career history and academic background is not provided in the available public filings and trading records.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.